Skip to main content
. 2020 Sep 12;11(1):1215–1224. doi: 10.1080/21505594.2020.1809322

Table 1.

Clinical characteristics of hvKp infection.

  Community-acquired infection (n = 10)
Healthcare-associated infection (n = 31)
Nosocomial infection (n = 117)
Clinical characteristic HvKp(7) cKp(3) HvKp(19) cKp(12) HvKp(53) cKp(64) P value
Basic demographics              
Age 75.29 ± 9.12 76.00 ± 22.52 76.84 ± 17.95 80.67 ± 11.55 78.21 ± 18.09 78.52 ± 12.65 0.914
Metastatic infection 2(28.6%) 0(0%) 8(42.1%) 0(0%) 21(39.6%) 14(21.9%) 0.037
Male 5(71.4%) 2(66.7%) 18(94.7%) 11(91.7%) 45(84.9%) 52(81.3%) 0.601
Underlying diseases              
Pulmonary disease 5(71.4%) 2(66.7%) 16(84.2%) 9(75.0%) 30(56.6%) 47(73.4%) 0.056
Diabetes 5(71.4%) 2(66.7%) 11(57.9%) 7(58.3%) 25(47.2%) 25(39.1%) 0.378
Cardiovascular disease 5(71.4%) 1(33.3%) 10(52.6%) 5(41.7%) 38(71.7%) 43(67.2%) 0.599
Cerebrovascular disease 1(14.3%) 0(0%) 7(36.8%) 6(50.0%) 35(66.0%) 28(43.8%) 0.016
Cancer 1(14.3%) 0(0%) 5(26.3%) 5(41.7%) 12(22.6%) 21(32.8%) 0.224
Surgery within 3 months 0(0%) 0(0%) 3(15.8%) 6(50.0%) 17(32.1%) 24(37.5%) 0.590
Digestive disease 3(42.9%) 0(0%) 7(36.8%) 5(41.7%) 30(56.6%) 35(54.7%) 0.836
Urinary disease 2(28.6%) 1(33.3%) 3(15.8%) 4(33.3%) 21(39.6%) 26(40.6%) 0.912
Usage of Glucocorticoid within 7 days 1(14.3%) 0(0%) 1(5.2%) 0(0%) 16(30.2%) 10(15.6%) 0.059
Antibiotics exposure within 90 d 0(0%) 0(0%) 9(47.4%) 4(33.3%) 49(92.5%) 61(95.3%) 0.516
Immunosuppression 1(14.3%) 0(0%) 5(26.3%) 5(41.7%) 21(39.6%) 30(46.9%) 0.431
Catheter              
Central intravenous catheter 0(0%) 0(0%) 8(42.1%) 0(0%) 42(79.2%) 42(65.6%) 0.103
Urinary catheter 0(0%) 0(0%) 7(36.8%) 5(41.7%) 48(90.6%) 49(76.6%) 0.045
Endotracheal tube 0(0%) 0(0%) 3(15.8%) 0(0%) 34(64.2%) 30(46.9%) 0.062
Gastrostomy tube 0(0%) 0(0%) 8(42.1%) 7(58.3%) 48(90.9%) 48(75.0%) 0.029
Drainage tube 0(0%) 0(0%) 1(5.2%) 4(33.3%) 19(35.8%) 22(34.4%) 0.868
Infection type              
Wound 1(14.3%) 0(0%) 0(0%) 1(8.3%) 2(3.8%) 5(7.8%) 0.599
Pneumonia 5(71.4%) 2(66.7%) 13(57.9%) 10(83.3%) 42(79.2%) 49(76.6%) 0.728
Urinary infection 1(14.3%) 1(33.3%) 8(21.1%) 1(8.3%) 17(32.1%) 17(26.6%) 0.513
Bacteremia 0(0%) 0(0%) 0(0%) 0(0%) 6(11.3%) 8(12.5%) 0.845
Liver abscess 0(0%) 0(0%) 1(5.2%) 0(0%) 1(1.9%) 2(3.1%) 1.000
Other abscess 1(14.3%) 0(0%) 5(26.3%) 0(0%) 3(5.7%) 1(1.6%) 0.225
Abdominal infection 1(14.3%) 0(0%) 0(0%) 0(0%) 7(13.2%) 7(10.9%) 0.706
Sepsis 2(28.6%) 0(0%) 10(52.6%) 4(33.3%) 43(81.1%) 38(59.4%) 0.011
WBC 13.29 ± 10.72 9.27 ± 2.05 14.55 ± 11.76 9.03 ± 3.68 9.87 ± 3.77 11.00 ± 5.25 0.192
NEU% 68.00 ± 15.56 68.47 ± 3.88 73.76 ± 19.67 78.08 ± 9.58 77.22 ± 10.06 77.73 ± 11.30 0.779
TP 72.14 ± 6.34 64.33 ± 4.51 63.63 ± 14.12 66.27 ± 5.06 63.86 ± 6.39 64.26 ± 5.49 0.712
ALB 40.29 ± 3.25 37.33 ± 1.53 34.53 ± 9.38 34.74 ± 4.19 33.19 ± 3.62 33.33 ± 4.39 0.852
CCI>4 2(28.6%) 0(0%) 8(42.1%) 8(66.7%) 29(54.7%) 39(60.9%) 0.497
SOFA>6 2(28.6%) 0(0%) 11(57.9%) 5(41.7%) 35(66.0%) 26(40.6%) 0.006
Admitted in the ICU# 1(14.3%)# 0(0%) 4(21.1%)# 1(8.3%) 15(28.3%) 26(40.6%) 0.164
30 day mortality * 1(14.3%) 0(0%) 1(5.2%) 3(25.0%) 8(15.1%) 13(20.3%) 0.464

The P value <0.05 was shown in the bold values. TP: Total protein; ALB: Albumin; WBC: White blood cell count; NEU%: Neutrophils percentage; CCI: Charlson comorbidity index; SOFA: Sequential organ failure assessment.*: Death or life-sustaining therapy withheld due to poor prognosis; #: patient with community-acquired infection or healthcare-associated infection was admitted or transferred to the ICU. : statistical tests were performed only for the nosocomial group.